263714-29-0

Basic information

• Product Name: 1-benzyl-7-methoxy-3,4-dihydronaphthalen-2(1H)-one
• Synonyms: 1-benzyl-7-methoxy-3,4-dihydronaphthalen-2(1H)-one
• CAS NO: 263714-29-0
• Molecular Weight: 266.34
• Mol File: 263714-29-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 422.4±45.0 °C(Predicted)
• Density: 1.133±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-benzyl-7-methoxy-3,4-dihydronaphthalen-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-7-methoxy-3,4-dihydronaphthalen-2(1H)-one(263714-29-0)
• EPA Substance Registry System: 1-benzyl-7-methoxy-3,4-dihydronaphthalen-2(1H)-one(263714-29-0)

Safety Data

• Hazardous Substances Data: 263714-29-0(Hazardous Substances Data)

Upstream product

• 40090-85-5 7-Methoxy-2-pyrrolidinyl-3,4-dihydronaphthalin 
• 100-39-0 benzyl bromide 
• 4133-34-0 7-methoxyl-2-tetralone 

Downstream Products

• 1410791-31-9 1-benzyl-8-methoxy-4,5-dihydro-1H-benzo[c]azepin-3(2H)-one 
• 1410789-81-9 1-benzyl-8-methoxy-2,3,4,5-tetrahydro-1H-benzo[c]azepine 
• 1410789-84-2 N-[2-(1-benzyl-2,3,4,5-tetrahydro-1H-benzo[c]azepin-8-yloxy)ethyl]-1-methyl-1H-imidazole-4-sulfonamide 
• 1410791-36-4 ethyl 1-benzyl-8-[2-(1-methyl-1H-imidazole-4-sulfonamido)ethoxy]-4,5-dihydro-1H-benzo[c]azepine-2(3H)-carboxylate 
• 1410791-34-2 C₂₇H₃₆N₂O₅ 
• 1410791-33-1 ethyl 1-benzyl-8-hydroxy-4,5-dihydro-1H-benzo[c]azepine-2(3H)-carboxylate 
• 1410791-32-0 ethyl 1-benzyl-8-methoxy-4,5-dihydro-1H-benzo[c]azepine-2(3H)-carboxylate 
• 58917-94-5 1-Benzyl-4-methoxy-tricyclo[7.4.1.0^2,7]tetradeca-2⁽⁷⁾,3,5-trien-14-ylamine 

Relevant articles and documents

Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors

The glycine transporter 1 (GlyT1) has emerged as a key novel target for the treatment of schizophrenia. Herein, we report the synthesis and biological evaluation of aminotetralines and aminochromanes as novel classes of competitive GlyT1 inhibitors. Starting from a high-throughput screening hit, structure-activity relationship studies led first to the discovery of aminotetralines displaying high GlyT1 potency and selectivity, with favorable pharmacokinetic properties. Systematic investigations of various parameters (e.g., topological polar surface area, number of hydrogen bond donors) guided by ex vivo target occupancy evaluation resulted in lead compounds possessing favorable brain penetration properties as for (7S,8R)-27a. Further optimization revealed compounds with reduced efflux liabilities as for aminochromane 51b. In an in vivo efficacy model (7S,8R)-27a, dose-dependently reversed L-687,414 induced hyperlocomotion in mice with an ED50 of 0.8 mg/kg. All these results suggest (7S,8R)-27a and 51b as new GlyT1 inhibitors worthy of further profiling.

PROCESS FOR PREPARING BICYCLIC AMINE DERIVATIVES

The present invention provides a process for preparing a bicyclic amine derivative of the for-mula (Ia) or (Ib), (Formulae (Ia) (Ib)) comprising the rhodium-catalyzed asymmetric hydrogenation of an enamine of the formula (II), (Formula (II)) in the presen

N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor

β-Aminotetralin derivatives of the formula: which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing a β-aminotetralin derivative as the active ingredient are described. The 62 -aminotetralins are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.